KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Other Operating Expenses (2017 - 2025)

Moderna (MRNA) has disclosed Other Operating Expenses for 8 consecutive years, with $452.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses fell 38.84% to $452.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $868.0 million, a 40.71% decrease, with the full-year FY2025 number at $868.0 million, down 40.71% from a year prior.
  • Other Operating Expenses was $452.0 million for Q4 2025 at Moderna, up from $207.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $2.2 billion in Q3 2023 to a low of $90.0 million in Q1 2025.
  • A 5-year average of $752.9 million and a median of $735.0 million in 2023 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 70201.85% in 2021, then tumbled 87.88% in 2024.
  • Moderna's Other Operating Expenses stood at $952.0 million in 2021, then skyrocketed by 101.47% to $1.9 billion in 2022, then plummeted by 51.56% to $929.0 million in 2023, then dropped by 20.45% to $739.0 million in 2024, then crashed by 38.84% to $452.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Other Operating Expenses are $452.0 million (Q4 2025), $207.0 million (Q3 2025), and $119.0 million (Q2 2025).